Health Care & Life Sciences » Biotechnology | Clovis Oncology Inc.

Clovis Oncology Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
323,228.00
482,677.00
528,588.00
266,183.00
563,731.00
520,146
Total Accounts Receivable
3,871.00
2,222.00
5,283.00
3,367.00
8,213.00
15,163
Inventories
-
-
-
-
47,969.00
27,072
Other Current Assets
1,497.00
6,273.00
5,830.00
9,860.00
7,027.00
9,918
Total Current Assets
328,596.00
491,172.00
539,701.00
279,410.00
626,940.00
572,299
Net Property, Plant & Equipment
955.00
2,718.00
4,946.00
4,440.00
4,007.00
26,524
Intangible Assets
319,329.00
278,955.00
160,827.00
78,239.00
84,778.00
115,004
Other Assets
755.00
13,361.00
7,912.00
2,468.00
19,505.00
149,733
Total Assets
649,635.00
786,206.00
713,386.00
364,557.00
735,230.00
865,306
ST Debt & Current Portion LT Debt
-
-
-
-
22,022.00
Accounts Payable
4,420.00
2,917.00
11,260.00
10,912.00
15,147.00
Income Tax Payable
-
411.00
-
-
-
Other Current Liabilities
16,532.00
44,444.00
64,316.00
54,685.00
44,348.00
Total Current Liabilities
20,952.00
47,772.00
75,576.00
65,597.00
81,517.00
Long-Term Debt
-
287,500.00
279,885.00
281,126.00
282,406.00
Provision for Risks & Charges
-
52,453.00
24,661.00
-
-
Deferred Taxes
74,955.00
66,851.00
31,133.00
-
-
Other Liabilities
55,842.00
-
1,481.00
21,468.00
3,671.00
Total Liabilities
151,749.00
454,576.00
412,736.00
368,191.00
367,594.00
Common Equity (Total)
497,886.00
331,630.00
300,650.00
3,634.00
367,636.00
Total Shareholders' Equity
497,886.00
331,630.00
300,650.00
3,634.00
367,636.00
Total Equity
497,886.00
331,630.00
300,650.00
3,634.00
367,636.00
Liabilities & Shareholders' Equity
649,635.00
786,206.00
713,386.00
364,557.00
735,230.00

About Clovis Oncology

View Profile
Address
5500 Flatiron Parkway
Boulder Colorado 80301
United States
Employees -
Website http://www.clovisoncology.com
Updated 07/08/2019
Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib.